Neoplasms, Basal Cell: Clinical Trials

55 trials for Neoplasms, Basal Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 8 recruiting, 5 active not recruiting, 5 terminated. 55 Phase 1, 18 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 155Completed 31, Recruiting 8, Active not recruiting 5, Terminated 5, Unknown 5, Suspended 1
Phase 218Completed 7, Recruiting 4, Active not recruiting 3, Terminated 2, Suspended 1, Unknown 1

Follow Neoplasms, Basal Cell: new trials by email Literature Review of Neoplasms, Basal Cell trials Research Report on Neoplasms, Basal Cell

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
KUP-101A - Cutaneous Melanoma, Mucosal Melanoma
Phase 1RecruitingKupando GmbH212026-07-032026-08-12
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
R-5780 - Solid Tumor, Adult, Solid Tumor
Phase 1RecruitingRise Therapeutics LLC332025-08-012026-09-18
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Tirbanibulin ointment 1%, non-ablative fractional laser - Keratinocyte Carcinoma, Basal Cell Carcinomas
Phase 1 / Phase 2RecruitingBruce Robinson, MD1002025-05-162025-09-17
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Phase 1 / Phase 2RecruitingUNC Lineberger Comprehensive Cancer Center1042025-02-062026-04-23
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
aminolevulinic acid HCL (ALA), BLU-U device model 4170E - Basal Cell Carcinoma (BCC)
Phase 1RecruitingNathalie Zeitouni202024-10-072026-01-29
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)162024-07-242026-10-14
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center562023-05-042026-08-12
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 1Active not recruitingUniversity of Southern California142023-01-092026-06-18
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female
Phase 1 / Phase 2RecruitingMarengo Therapeutics, Inc.3662023-01-042026-08-11
Intratumoral phIL12 GET
phIL12 GET - Basal Cell Carcinoma
Phase 1CompletedInstitute of Oncology Ljubljana92021-09-282023-12-14
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Doxorubicin-containing MNA, Placebo-containing MNA - Basal Cell Carcinoma
Phase 1 / Phase 2Active not recruitingSkinJect, Inc.252021-09-242023-04-14
A Beta-only IL-2 ImmunoTherapY Study
MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor
Phase 1 / Phase 2Active not recruitingMedicenna Therapeutics, Inc.1602021-08-272026-10-30
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
IFx-Hu2.0 - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Phase 1CompletedTuHURA Biosciences, Inc.52021-06-102024-08-02
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
INCB099318 - Advanced Solid Tumors, MSI-H/dMMR Tumors
Phase 1TerminatedIncyte Corporation1052021-03-262025-10-16
Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer
Imvamune - Non-melanoma Skin Cancer, Basal Cell Carcinoma
Phase 1 / Phase 2TerminatedIvan Litvinov12020-11-162024-03-07
Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
AIV001, AIV001 suspension - Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Phase 1CompletedAiViva BioPharma, Inc.262020-08-182026-11-04
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
Placebo-containing MNA, 25 µg doxorubicin-containing MNA, 50 µg doxorubicin-containing MNA - Basal Cell Carcinoma
Phase 1TerminatedSkinJect, Inc.132020-06-102026-04-16
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RP1, intra-tumoral injection, oncolytic virus - Merkel Cell Carcinoma, Basal Cell Carcinoma
Phase 1 / Phase 2Active not recruitingReplimune, Inc.692020-05-152026-04-22
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Phase 1Active not recruitingNational Cancer Institute (NCI)122019-11-082026-11-13
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
Copaxone - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma
Phase 1UnknownUniversity of Kansas Medical Center102019-07-262023-05-19

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Carcinoma, Basal Cell (52)  ·  Skin Neoplasms (14)  ·  Melanoma (12)  ·  Carcinoma, Merkel Cell (9)  ·  Carcinoma, Squamous Cell (7)  ·  Neoplasms (6)  ·  Basal Cell Nevus Syndrome (5)  ·  Squamous Cell Carcinoma of Head and Neck (5)  ·  Breast Neoplasms (4)  ·  Endometrial Neoplasms (4)  ·  Lymphoma, T-Cell, Cutaneous (4)  ·  Medulloblastoma (4)  ·  Neoplasm Metastasis (4)  ·  Small Cell Lung Carcinoma (4)

Broader conditions

Neoplasms by Histologic Type (55)  ·  Neoplasms, Glandular and Epithelial (55)  ·  Carcinoma (51)  ·  Neoplasms (49)  ·  Neoplasms by Site (24)  ·  Skin Diseases (22)  ·  Skin and Connective Tissue Diseases (22)  ·  Neoplasms, Germ Cell and Embryonal (20)  ·  Neoplasms, Nerve Tissue (20)  ·  Neuroectodermal Tumors (20)  ·  Neuroendocrine Tumors (15)  ·  Nevi and Melanomas (12)  ·  Adenocarcinoma (10)  ·  DNA Virus Infections (10)

Interventions

1-phenyl-3,3-dimethyltriazene (5)  ·  Photochemotherapy (5)  ·  pembrolizumab (4)  ·  Biopsy (3)  ·  HhAntag691 (3)  ·  Aminolevulinic Acid (2)  ·  CTLA-4 Antigen (2)  ·  Fluorouracil (2)  ·  Ipilimumab (2)  ·  Irinotecan (2)  ·  Nivolumab (2)  ·  Prednisone (2)  ·  Sirolimus (2)  ·  deltacortene (2)  ·  gusacitinib (2)

Sponsors

Case Comprehensive Cancer Center (3)  ·  Novartis Pharmaceuticals (3)  ·  Shahid Beheshti University of Medical Sciences (3)  ·  Ascend Biopharmaceuticals Ltd (2)  ·  Merete Haedersdal (2)  ·  National Cancer Institute (NCI) (2)  ·  Roswell Park Cancer Institute (2)  ·  SkinJect, Inc. (2)  ·  AiViva BioPharma, Inc. (1)  ·  Anne Chang (1)  ·  Blaze Bioscience Australia Pty Ltd (1)  ·  Bristol-Myers Squibb (1)  ·  Bruce Robinson, MD (1)  ·  Eastern Virginia Medical School (1)  ·  Genentech, Inc. (1)

Countries

United States (38)  ·  Australia (4)  ·  Canada (4)  ·  Switzerland (4)  ·  United Kingdom (4)  ·  Denmark (3)  ·  Spain (3)  ·  Finland (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Ireland (1)

Top investigators

Evan J Lipson (2)  ·  Zohreh Tehranchi-nia, assist.prof. (2)  ·  Allan R. Oseroff, MD, PhD (1)  ·  Allen E. Bale, MD (1)  ·  Anna Bar (1)  ·  Anne Lynn S Chang, MD (1)  ·  Antoinette F. Hood, MD (1)  ·  Arash Yavari, MBBS (1)  ·  Ashwin Somasundaram, MD (1)  ·  Bruce Robinson, MD (1)  ·  Clement Leong (1)  ·  Edward V. Maytin, MD, PhD (1)

Results publications

PMID 19196482, PMID 20855696, PMID 27467121, PMID 28250200, PMID 32503950, PMID 34401600, PMID 35276694, PMID 36821617, PMID 38252910, PMID 38758815, PMID 39400600, PMID 40230575, PMID 42580817

NIH funding

2023 (2), P30CA043703 (2), UM1CA186691 (2), 2008 (1), 2009 (1), 2014 (1), 2019 (1), 2025 (1), P30CA016056 (1), P30CA124435 (1), R21CA109670 (1), U01CA062502 (1)